Your browser doesn't support javascript.
loading
Favorable four-yr outcome after renal transplantation in a patient with complement factor H antibody and CFHR1/CFHR3 gene mutation-associated HUS.
Grenda, Ryszard; Jarmuzek, Wioletta; Rubik, Jacek; Prokurat, Sylwester; Miklaszewska, Monika; Drozdz, Dorota; Zachwieja, Katarzyna; Ardissino, Gianluigi; Hofer, Johannes.
Affiliation
  • Grenda R; Department of Nephrology, Kidney Transplantation and Hypertension, The Children's Memorial Health Institute, Warsaw, Poland.
  • Jarmuzek W; Department of Nephrology, Kidney Transplantation and Hypertension, The Children's Memorial Health Institute, Warsaw, Poland.
  • Rubik J; Department of Nephrology, Kidney Transplantation and Hypertension, The Children's Memorial Health Institute, Warsaw, Poland.
  • Prokurat S; Department of Nephrology, Kidney Transplantation and Hypertension, The Children's Memorial Health Institute, Warsaw, Poland.
  • Miklaszewska M; Department of Pediatric Nephrology, Collegium Medicum of the Jagiellonian University, Cracow, Poland.
  • Drozdz D; Department of Pediatric Nephrology, Collegium Medicum of the Jagiellonian University, Cracow, Poland.
  • Zachwieja K; Department of Pediatric Nephrology, Collegium Medicum of the Jagiellonian University, Cracow, Poland.
  • Ardissino G; Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
  • Hofer J; Department of Pediatrics, Neurology and Nephrology, Innsbruck Medical University, Innsbruck, Austria.
Pediatr Transplant ; 19(6): E130-4, 2015 Sep.
Article in En | MEDLINE | ID: mdl-26087050
UNLABELLED: aHUS is a clinical challenge for successful renal transplantation. CASE REPORT: A 14-yr-old girl lost her kidneys at the age of 7, due to CFH antibodies and CFH-related protein (CFHR1/CFHR3) homozygous deletion-associated aHUS. CFH, CFI, and MCP gene mutations were excluded. The patient was a candidate for renal transplantation despite persistent presence of CFH antibodies (up to 539 AU/mL). Treatment with MMF, IVIG, and repeated PF (n = 8) was introduced while being placed on urgent waiting list. Three years after aHUS onset, the patient underwent the deceased donor renal transplantation "under cover" of PF, as PF was performed directly prior to surgery and, then, PFs were repeated up to overall 14 sessions. Quadruple immunosuppression (basiliximab + tacrolimus + MMF + prednisolone) was used. Moderate symptoms of aHUS (hemolysis, low platelets, and low C3) were present within first seven days post-transplant and then normalized with PF therapy. The patient remained stable during four yr of further follow-up after transplantation. CONCLUSION: Specific pre- and post-transplant management allowed successful renal transplantation in a CFH antibody-positive patient.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Autoantibodies / Complement C3b Inactivator Proteins / Blood Proteins / Kidney Transplantation / Complement Factor H / Atypical Hemolytic Uremic Syndrome Type of study: Risk_factors_studies Limits: Adolescent / Female / Humans Language: En Journal: Pediatr Transplant Journal subject: PEDIATRIA / TRANSPLANTE Year: 2015 Type: Article Affiliation country: Poland

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Autoantibodies / Complement C3b Inactivator Proteins / Blood Proteins / Kidney Transplantation / Complement Factor H / Atypical Hemolytic Uremic Syndrome Type of study: Risk_factors_studies Limits: Adolescent / Female / Humans Language: En Journal: Pediatr Transplant Journal subject: PEDIATRIA / TRANSPLANTE Year: 2015 Type: Article Affiliation country: Poland